212 related articles for article (PubMed ID: 37798027)
1. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
[TBL] [Abstract][Full Text] [Related]
2. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
3. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
5. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
7. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
[TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Yokoyama Y; Matsuzaki H; Nagai Y; Yoshioka Y; Shinagawa T; Sonoda H; Yamamoto Y; Oba K; Ishihara S
BMC Cancer; 2023 May; 23(1):450. PubMed ID: 37198556
[TBL] [Abstract][Full Text] [Related]
10. Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial.
Zheng R; Wang BS; Li Z; Chi P; Xu B
BMJ Open; 2023 Mar; 13(3):e066976. PubMed ID: 36927585
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
[TBL] [Abstract][Full Text] [Related]
12. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
13. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
15. Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
Kang MK; Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Cho SH; Seo AN; Kim DW; Kim J; Baek SJ; Kim JH; Kim JY; Ha GW; Park EJ; Park IJ; Kim CH; Kang H; Choi GS
BMC Cancer; 2023 Nov; 23(1):1059. PubMed ID: 37923987
[TBL] [Abstract][Full Text] [Related]
16. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
[TBL] [Abstract][Full Text] [Related]
17. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
18. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
20. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
